Skip to main content
Editorial
September 29, 2022

Status Migrainosus
One of the Most Poorly Understood but Important Complications of Migraine

This article has related content.
VIEW RELATED CONTENT
January 17, 2023 issue
100 (3) 107-108

Abstract

Migraine is the second most common and disabling disease worldwide,1 and some of the associated disability can be attributed to complications of the disease. Status migrainosus, whereby an attack exceeds 72 hours in duration,2 is a complication of migraine that has historically been very understudied. It is unclear how common it is, given limited data, but the few existing prevalence studies have estimated that anywhere from 3% to 20% of people with migraine may experience status migrainosus.3-5 What little evidence is available suggests that it is a considerable public health problem; it is associated with significant disability,5 and people with status migrainosus have a worse migraine prognosis5 and a higher risk of suicide6 when compared with people with migraine who do not experience status migrainosus. People with status migrainosus are also frequently hospitalized for management,4,5 and admissions are incredibly costly, with estimates varying between ∼USD $3,800 and 7,000 per admission.7,8 Unfortunately, existing inpatient therapies have very low levels of evidence to support their use and may have low efficacy rates.9

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858.
2.
Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
3.
Pryse-Phillips W, Aubé M, Bailey P, et al. A clinical study of migraine evolution. Headache. 2006;46(10):1480-1486.
4.
Beltramone M, Donnet A. Status migrainosus and migraine aura status in a French tertiary-care center: an 11-year retrospective analysis. Cephalalgia. 2014;34(8):633-637.
5.
Orr SL, Turner A, Kabbouche MA, et al. The profile and prognosis of youth with status migrainosus: results from an observational study. Headache. 2020;60(5):878-888.
6.
Harnod T, Lin C-L, Kao C-H. Risk and predisposing factors for suicide attempts in patients with migraine and status migrainosus: a nationwide population-based study. J Clin Med. 2018;7(9):269.
7.
Modi SY, Dharaiya D, Katramados AM, Mitsias P. Predictors of prolonged hospital stay in status migrainosus. Neurohospitalist. 2016;6(4):141-146.
8.
Nelson GR, Bale JF, Kerr LM. Outcome and cost of inpatient hospitalization for intravenous dihydroergotamine treatment of refractory pediatric headache. Pediatr Neurol. 2017;66:76-81.
9.
Iljazi A, Chua A, Rich-Fiondella R, et al. Unrecognized challenges of treating status migrainosus: an observational study. Cephalalgia. 2020;40(8):818-827.
10.
VanderPluym JH, Mangipudi K, Mbonde AA, et al. Incidence of status migrainosus in Olmsted County, Minnesota, United States: characterization and predictors of recurrence. Neurology. 2022;100(3):e255-e263.

Information & Authors

Information

Published In

Neurology®
Volume 100Number 3January 17, 2023
Pages: 107-108
PubMed: 36175154

Publication History

Received: August 26, 2022
Accepted: September 12, 2022
Published online: September 29, 2022
Published in print: January 17, 2023

Permissions

Request permissions for this article.

Disclosure

S.L. Orr receives royalties from Cambridge University Press. She serves on the editorial boards of Headache, Neurology, and the American Migraine Foundation. She also has research funding from the Canadian Institutes of Health Research, the Alberta Children's Hospital Research Institute, and the Cumming School of Medicine. She has received speaker honoraria from the American Headache Society for delivering a Resident Education for Assessment and Care for Headache (REACH) Program lecture. Go to Neurology.org/N for full disclosures.

Study Funding

The authors report no targeted funding.

Authors

Affiliations & Disclosures

Notes

Correspondence Dr. Orr serena.orr@medportal.ca
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Real‐world approaches to outpatient treatment of status migrainosus: A survey study, Headache: The Journal of Head and Face Pain, 64, 8, (1040-1048), (2024).https://doi.org/10.1111/head.14769
    Crossref
  2. Managing and Preventing Migraine in the Emergency Department: A Review, Annals of Emergency Medicine, 82, 6, (732-751), (2023).https://doi.org/10.1016/j.annemergmed.2023.05.024
    Crossref
Loading...

Media

Figures

Other

Tables

Share

Share

Share article link

Share

Get Access

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • customerservice@lww.com

We appreciate your patience during this time and apologize for any inconvenience.

References

References

1.
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858.
2.
Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
3.
Pryse-Phillips W, Aubé M, Bailey P, et al. A clinical study of migraine evolution. Headache. 2006;46(10):1480-1486.
4.
Beltramone M, Donnet A. Status migrainosus and migraine aura status in a French tertiary-care center: an 11-year retrospective analysis. Cephalalgia. 2014;34(8):633-637.
5.
Orr SL, Turner A, Kabbouche MA, et al. The profile and prognosis of youth with status migrainosus: results from an observational study. Headache. 2020;60(5):878-888.
6.
Harnod T, Lin C-L, Kao C-H. Risk and predisposing factors for suicide attempts in patients with migraine and status migrainosus: a nationwide population-based study. J Clin Med. 2018;7(9):269.
7.
Modi SY, Dharaiya D, Katramados AM, Mitsias P. Predictors of prolonged hospital stay in status migrainosus. Neurohospitalist. 2016;6(4):141-146.
8.
Nelson GR, Bale JF, Kerr LM. Outcome and cost of inpatient hospitalization for intravenous dihydroergotamine treatment of refractory pediatric headache. Pediatr Neurol. 2017;66:76-81.
9.
Iljazi A, Chua A, Rich-Fiondella R, et al. Unrecognized challenges of treating status migrainosus: an observational study. Cephalalgia. 2020;40(8):818-827.
10.
VanderPluym JH, Mangipudi K, Mbonde AA, et al. Incidence of status migrainosus in Olmsted County, Minnesota, United States: characterization and predictors of recurrence. Neurology. 2022;100(3):e255-e263.